Mutagenesis after therapy for Hodgkin's disease.
Therapy for Hodgkin's disease has been associated with a significant increase in risk for second cancers. To begin an investigation of the association of therapy-induced genetic damage with this risk, somatic mutations at the hypoxanthine phosphoribosyltransferase locus were measured in lymphocytes from patients previously treated for Hodgkin's disease. The results demonstrate that a subset of patients have persistently elevated mutation frequencies, perhaps suggesting that these individuals are among those at significant risk of second cancer development.
Kelsey
K T
KT
Department of Cancer Biology, Harvard School of Public Health, Boston, Massachusetts.
Caggana-Aviles
M
M
Mauch
P
P
Coleman
C N
CN
Shulman
L N
LN
Liber
H L
HL
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D006689:Hodgkin Disease / Q000235:genetics / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D016296:Mutagenesis; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects